On January 29, 2020, 3D Medicines announced that the clinical trial application of its self-developed category 1 innovative drug 3D011 has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, marking the approval of 3D Medicines Already have the original research ability to research and develop innovative drugs with global intellectual property rights, which has laid a solid foundation for achieving the company’s long-term sustainable development strategic goals.
3D011 is a class I innovative drug for the treatment of advanced solid tumors. The parent drug has a good inhibitory effect on related kinases. Clinical data has fully proved its good anti-tumor efficacy. The R&D team of 3D Medicine improved its pharmacokinetic properties through prodrug design, thereby reducing its systemic toxicity, and obtained the innovative drug 3D011.
Medicilon can undertake the synthesis of special reagents, intermediates and molecular fragments, preparation of standard products, synthesis design and preparation of impurities or metabolites, synthesis of stable isotope internal standards and synthesis of tritiated compounds.
Aim at chemical synthesis through Ibuprofen
Medicilon FTE services & FFS services - flexible and efficient cooperation model
Medicilon Drug Discovery--Opening the Door of Innovative Drugs with Science and Professionalism
Medicilon was fortunate to cooperate with 3D Medicine in the 3D011 research and development project. Under the guidance of 3D Medicine’s R&D team, Medicilon’s pharmaceutical research team helped 3D Medicine overcome the difficulties in the process of drug synthesis and purification and helped it complete the development of APIs.
Medicilon congratulates the phased success of the 3D011 project, and looks forward to cooperating with 3D Medicine and many innovative drug companies in the future to create a thriving and flourishing innovative drugs, and to watch a new chapter in human health!
3D Medicines Inc. is a biomedical company in the stage of advanced clinical development and early commercialization. Adhering to the concept of “helping cancer patients live longer and better”, it aims at the future trend of slowing cancer treatment , Focusing on developing a new generation of differentiated tumor immunotherapy drugs for cancer patients around the world, extending the survival time of cancer patients and improving the quality of life of patients. The company’s product line includes a new generation of biomacromolecule drugs and small molecule chemical drugs, and has a team with international new drug development, registration and commercial operation capabilities.
Medicilon (stock code: 688202) was established in 2004 and is headquartered in Shanghai. It is committed to providing a full range of preclinical new drug research services for global pharmaceutical companies, research institutions and scientific researchers. Medicilon’s one-stop integrated service helps customers accelerate the development of new drugs with strong project management and more efficient and cost-effective R&D services. The services cover the entire process of preclinical new drug research in medicine, including drug discovery, pharmaceutical research and clinical trials, pre-research. Medicilon grows together with high-quality customers at home and abroad, and provides new drug research and development services to more than 700 customers around the world. Medicilon will continue to base itself on a global perspective, gather Chinese innovation, and contribute to human health!
contact us
Email: marketing@medicilon.com
Tel: +86 (21) 5859-1500
Relevant
news
marketing@medicilon.com
